Predictors of antipsychotic medication change

被引:0
作者
Michael J. Sernyak
Douglas Leslie
Robert Rosenheck
机构
[1] Psychiatry Service,Department of Psychiatry
[2] 116A,Department of Psychiatry
[3] VA Connecticut Healthcare System,undefined
[4] West Haven Campus,undefined
[5] VA Northeast Program Evaluation Center,undefined
[6] Yale University School of Medicine,undefined
[7] Yale University Schools of Medicine and Epidemiology and Public Health,undefined
来源
The Journal of Behavioral Health Services & Research | 2005年 / 32卷
关键词
Schizophrenia; Health Promotion; Powerful Predictor; Clinical Variable; Service Utilization;
D O I
暂无
中图分类号
学科分类号
摘要
Atypical antipsychotics account for more than 60% of antipsychotic prescriptions written for the treatment of schizophrenia. While switching from one antipsychotic to another is a dynamic process, there has been no research on individual patient and institutional characteristics that predict antipsychotic switching. VA national administrative data were used to identify patients (n=9660) with schizophrenia maintained on antipsychotic medication. Logistic regression was used to identify predictors of medication switching. Independent variables included information about service utilization, sociodemographic and clinical variables as well as institutional characteristics. This model was repeated for more specific switches between classes of medications and between specific medications. High levels of outpatient and inpatient service use were the most powerful predictors of switching. Sociodemographic, institutional, diagnostic, and functional measures were also predictive in some cases. Controlling for independent sociodemographic, diagnostic, and functional measures, frequency of clinical contact was the most robust predictor of switching antipsychotics.
引用
收藏
页码:85 / 94
页数:9
相关论文
共 21 条
[1]  
Leslie D(2001)The effect of institutional fiscal stress on the use of atypical antipsychotic medications in the treatment of schizophrenia Journal of Nervous and Mental Disease 189 377-383
[2]  
Rosenheck R(2002)From conventional antipsychotics to atypicals and back: dynamic processes in the diffusion of new medications American Journal of Psychiatry 159 1534-1540
[3]  
Leslie D(1998)Access to public mental health services: determinants of population coverage Medical Care 36 503-512
[4]  
Rosenheck R(2001)The efficacy and safety of ripseridone for the treatment of geriatric psychosis Journal of Clinical Psychopharmacology 21 583-587
[5]  
Rosenheck R(2003)Influence of race/ethnicity on antipsychotic prescribing practices in a community mental health center Psychiatric Services 54 177-179
[6]  
Stolar M(2001)A novel augmentation strategy for treating resistant major depression American Journal of Psychiatry 158 131-134
[7]  
Hwang J(2001)Delays in adopting evidence-based dosages of conventional antipsychotics Psychiatric Services 52 1242-1244
[8]  
Yang C(2003)Combination antipsychotic therapy in clinical practice Psychiatric Services 54 55-59
[9]  
Yu H(undefined)undefined undefined undefined undefined-undefined
[10]  
Woods S(undefined)undefined undefined undefined undefined-undefined